Dental Literature Watch · Guideline · Oral medicine
ADA Living Guideline: Do Not Use Toluidine Blue to Decide on Biopsy
TL;DR
- The panel recommends against vital staining (toluidine blue) as an adjunct — both for screening adults with no mucosal abnormality, and for deciding whether to biopsy an abnormality you can see.
- Conditional recommendation, very low certainty evidence, in both directions.
- Two good practice statements: perform a clinical oral examination in all adult patients, including asymptomatic ones with no visible lesion.
- Biopsy remains the first choice for a definitive diagnosis of a potentially malignant disorder or oral squamous cell carcinoma.
- It is a living guideline — expect revision rather than a decade of silence.
What was asked, and what came back
| Question | Recommendation | Strength |
|---|---|---|
| Vital staining to screen adults with no mucosal abnormality | Against | Conditional, very low certainty |
| Vital staining to decide on biopsy in adults with an abnormality | Against | Conditional, very low certainty |
| Clinical oral examination in all adults | Do it | Good practice statement |
| Definitive diagnosis | Biopsy | Good practice statement |
The panel weighed more than accuracy
Using the GRADE Evidence-to-Decision framework, they also considered resources required, equity, acceptability, and feasibility.
An adjunct that costs money and chair time while not improving the biopsy decision fails on several of those at once.
Using the GRADE Evidence-to-Decision framework, they also considered resources required, equity, acceptability, and feasibility.
An adjunct that costs money and chair time while not improving the biopsy decision fails on several of those at once.
💎 Insight — what this means chairside
The adjunct industry keeps promising to solve a problem it has not solved
Every few years a device or dye is marketed as the answer to oral cancer detection.
This guideline says plainly that toluidine blue does not improve on looking carefully and biopsying what looks wrong.
Every few years a device or dye is marketed as the answer to oral cancer detection.
This guideline says plainly that toluidine blue does not improve on looking carefully and biopsying what looks wrong.
The real recommendation is the boring one
A clinical oral examination in every adult, including the asymptomatic patient with nothing visible.
The most common failure in oral cancer detection is not a missed dye result — it is a mucosal exam that never happened because the appointment was about a filling.
A clinical oral examination in every adult, including the asymptomatic patient with nothing visible.
The most common failure in oral cancer detection is not a missed dye result — it is a mucosal exam that never happened because the appointment was about a filling.
A negative adjunct result is the dangerous outcome
If a lesion looks suspicious, a reassuring stain does not make it less suspicious.
The value of removing the adjunct from the pathway is that it removes a chance to be falsely reassured.
If a lesion looks suspicious, a reassuring stain does not make it less suspicious.
The value of removing the adjunct from the pathway is that it removes a chance to be falsely reassured.
⚠️ The catch
Conditional, on very low certainty evidence
This is a recommendation against, made on weak data, which means it reflects the absence of demonstrated benefit rather than proof of harm.
Conditional recommendations are the ones where individual circumstances legitimately change the answer.
This is a recommendation against, made on weak data, which means it reflects the absence of demonstrated benefit rather than proof of harm.
Conditional recommendations are the ones where individual circumstances legitimately change the answer.
It covers vital staining only
This guideline addresses toluidine blue. It is not a verdict on autofluorescence devices, brush cytology, or salivary diagnostics.
Being a living guideline, those may be addressed in later instalments — do not extrapolate today.
This guideline addresses toluidine blue. It is not a verdict on autofluorescence devices, brush cytology, or salivary diagnostics.
Being a living guideline, those may be addressed in later instalments — do not extrapolate today.
⚡ Bottom line
- Asymptomatic adult, nothing visible → do the clinical oral examination. Do not add vital staining.
- Suspicious white or red patch → biopsy or refer. Do not let a stain result adjudicate it.
- Sales rep offering a staining kit → the ADA panel recommends against it, on both indications.
- Lesion looks benign but persists → persistence is the indication for biopsy; no adjunct changes that.
🧪 Questions
Tap an answer — instant grade, deciding line, and the trap.
A 62-year-old man who smokes has a 2 cm homogeneous white patch on the lateral border of his tongue, present for at least three months and not wiping away. You have a toluidine blue kit in the practice. Following the 2026 ADA living guideline, what is the appropriate next step?
Deciding line: the panel recommends against vital staining for deciding on biopsy in patients with a mucosal abnormality, and biopsy remains the first choice for definitive diagnosis of a persistent lesion in a smoker. Trap: the fourth option is the engineered trap and the genuinely dangerous one, since a negative stain in a suspicious lesion produces false reassurance; watchful waiting for three months in a persistent lesion that has already been present three months compounds delay without adding information.